Healthcare Services company Suraksha Diagnostic announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: For Q4FY25, the company reported revenue from operations of Rs 651.0 million, reflecting a growth of 18.0% compared to the same quarter last year. EBITDA for Q4FY25 reached Rs 200.1 million compared to Rs 204.5 million in the previous year. The EBITDA margin for Q4FY25 stood at 30.7%. PAT for Q4FY25 stood at Rs 71.7 million, reflecting a growth of 13.4% year-on-year. The PAT margin for Q4FY25 was 11.0%, compared to 11.5% in the same quarter last year During the quarter ended 31 March 2025, the Company entered into a Share Subscription Agreement to acquire 95,841 equity shares of Rs10/- each in Fetomat Wellness Private Limited ("Fetomat"), representing a 16.17% stake, at Rs 100 lakhs. Subsequently, after 31 March 2025, the Company entered into Share Purchase Agreements with existing shareholders of Fetomat to acquire an additional 2,77,582 equity shares of Rs10/- each, increasing its total equity stake to approximately 63%, thereby obtaining control and making Fetomat a subsidiary of the Company FY25 Financial Highlights: For the year ended FY25, revenue amounted to Rs 2,520.9 million, a growth of 15.3 % year-on-year. For FY25, EBITDA totaled Rs 850.9 million, a growth of 15.6% year-on-year. The EBITDA margin for FY25 stood at 33.8%, up from 33.7% in the corresponding period. For FY25, PAT reached Rs 309.8 million, an increase of 34.0 % year-on-year. Added total of 7 Centers in the year with 1 big, 1 medium, 3 small centers and 2 PPP centers. Commenting on the results Ritu Mittal, Joint Managing Director & CEO said, - “We are pleased to present our first full-year financial results post-listing, marking a strong performance across FY25 with revenue growing by 15.3% year-on-year and PAT increasing by 34.0% year-on-year. During the year, we added 7 centers, despite diversions such as the management’s focus on the IPO, coupled with unfavorable events such as the doctors’ strike and the Bangladesh issue. Looking ahead, we are optimistic about expansion, with approvals already in place for the majority of our planned centers. We anticipate adding 15-18 centers in FY26, supporting our long-term growth trajectory. The acquisition of Fetomat Wellness Private Limited ('Fetomat’) in April 2025, marked our entry into the field of genomic medicine. Fetomat operates in the healthcare segment with a focus on pregnancy care, women’s ultrasound scanning, prenatal diagnostics, therapy, genetic counseling, and medical training for doctors. We believe this acquisition brings significant synergies with our existing operations and opens new avenues for sustainable growth. We expect our EBIDTA and PAT margins to improve further as we scale our operations and our centers reach maturity. With higher throughput, improved operating leverage and tighter cost controls, we expect meaningful margin expansion in our mature centers. As newer centers stabilize and start contributing significantly, we anticipate a stronger, more profitable financial profile across the network.” Result PDF